Atria Investments Inc Takes Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Atria Investments Inc acquired a new stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,009 shares of the company’s stock, valued at approximately $112,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Securities Group LLC acquired a new stake in Pliant Therapeutics during the 2nd quarter valued at approximately $59,000. SG Americas Securities LLC acquired a new stake in Pliant Therapeutics during the 1st quarter valued at approximately $107,000. Deerfield Management Company L.P. Series C acquired a new stake in Pliant Therapeutics during the 2nd quarter valued at approximately $126,000. China Universal Asset Management Co. Ltd. increased its position in Pliant Therapeutics by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,694 shares of the company’s stock valued at $131,000 after purchasing an additional 4,607 shares during the period. Finally, ProShare Advisors LLC increased its position in Pliant Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 14,489 shares of the company’s stock valued at $216,000 after purchasing an additional 1,203 shares during the period. Institutional investors and hedge funds own 97.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PLRX. Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a research report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Pliant Therapeutics in a research report on Thursday, August 8th. Oppenheimer reduced their price objective on shares of Pliant Therapeutics from $48.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Leerink Partnrs raised shares of Pliant Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Pliant Therapeutics in a research report on Friday, November 8th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Pliant Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $40.57.

Pliant Therapeutics Price Performance

Shares of PLRX opened at $12.98 on Monday. Pliant Therapeutics, Inc. has a 12-month low of $10.22 and a 12-month high of $19.62. The business’s fifty day moving average is $13.11 and its 200 day moving average is $12.75. The company has a quick ratio of 10.26, a current ratio of 10.26 and a debt-to-equity ratio of 0.09. The stock has a market cap of $789.88 million, a P/E ratio of -3.89 and a beta of 1.08.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.